Page 99 - Read Online

122. Coussens LM. Zitvogel L, Palucka AK. Neutralizing tumor- Fouladi M, Gilles FH, Judkins AR, Sposto R, Asgharzadeh S. Tumor-
promoting chronic inflammation: A magic bullet? (vol 339, pg 286, associated macrophages in SHH subgroup of medulloblastomas. Clin
2013). Science 2013;339:286-91. Cancer Res 2015;21:1457-65.
123. Schmid MC, Franco I, Kang SW, Hirsch E, Quilliam LA, Varner JA. 131. Sampaio NG, Yu W, Cox D, Wyckoff J, Condeelis J, Stanley ER,
PI3-kinase gamma promotes Rap1a-mediated activation of myeloid Pixley FJ. Phosphorylation of CSF-1R Y721 mediates its association
cell integrin alpha4beta1, leading to tumor inflammation and growth. with PI3K to regulate macrophage motility and enhancement of
PloS one 2013;8:e60226. tumor cell invasion. J Cell Sci 2011;124:2021-31.
124. Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners 132. Mouchemore KA, Sampaio NG, Murrey MW, Stanley ER, Lannutti
in crime in inflammation in rheumatoid arthritis and beyond? Nature BJ, Pixley FJ. Specific inhibition of PI3K p110delta inhibits CSF-
reviews. Immunology 2007;7:191-201. 1-induced macrophage spreading and invasive capacity. FEBS J
125. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of 2013;280:5228-36.
microglia. Physiol Rev 2011;91:461-553. 133. Carrasco-Garcia E, Saceda M, Martinez-Lacaci I. Role of receptor
126. Wei J, Gabrusiewicz K, Heimberger A. The controversial tyrosine kinases and their ligands in glioblastoma. Cells 2014;3:199-235.
role of microglia in malignant gliomas. Clin Dev Immunol
2013;2013:285246. 134. Chi AS, Wen PY. Inhibiting kinases in malignant gliomas. Expert
127. Markovic DS, Vinnakota K, Chirasani S, Synowitz M, Raguet H, Opin Ther Targets 2007;11:473-96.
Stock K, Sliwa M, Lehmann S, Kälin R, van Rooijen N, Holmbeck 135. De Witt Hamer PC. Small molecule kinase inhibitors in glioblastoma:
K, Heppner FL, Kiwit J, Matyash V, Lehnardt S, Kaminska B, Glass a systematic review of clinical studies. Neuro Oncol 2010;12:304-16.
R, Kettenmann H. Gliomas induce and exploit microglial MT1- 136. Arteaga CL, Baselga J. Tyrosine kinase inhibitors: why does the
MMP expression for tumor expansion. Proc Natl Acad Sci U S A current process of clinical development not apply to them? Cancer
2009;106:12530-5. cell 2004;5:525-31.
128. Ellert-Miklaszewska A, Dabrowski M, Lipko M, Sliwa M, Maleszewska 137. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu
M, Kaminska B. Molecular definition of the pro-tumorigenic phenotype S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker
of glioma-activated microglia. Glia 2013;61:1178-90. D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J,
129. Lisi L, Laudati E, Navarra P, Dello Russo C. The mTOR kinase Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. Antitumor
inhibitors polarize glioma-activated microglia to express a M1 activity of rapamycin in a Phase I trial for patients with recurrent
phenotype. J Neuroinflammation 2014;11:125. PTEN-deficient glioblastoma. PLoS Med 2008;5:e8.
130. Margol AS, Robison NJ, Gnanachandran J, Hung LT, Kennedy RJ, 138. Trail data from ClinicalTrails.gov [Interent]. New York: U.S. National
Vali M, Dhall G, Finlay JL, Erdreich-Epstein A, Krieger MD, Drissi R, Institutes of Health. Available from: https://clinicaltrials.gov/.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ March 11, 2016 ¦ 89